NCT04284202 2020-02-25
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
The Affiliated Hospital of Qingdao University
Phase 2 Unknown
The Affiliated Hospital of Qingdao University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Duke University